Andrew Laughlin is a member in the life sciences practice group where he focuses his practice on the preparation and prosecution of patent applications related to chemical, biotechnology, pharmaceuticals, nanotechnology, materials science, diagnostics, pulp and paper, medical and mechanical devices, and related software inventions.
Andrew has expertise working with high throughput screening systems, microfluidic devices, diagnostic markers, implantable medical devices, conjugated polymers, and quantum dots. Representative client technologies include microfluidics, micro/nano technologies, MEMS, applied chemistry, flexible electronics, organic light-emitting diodes (OLEDs), photonics, ophthalmic devices, drug delivery devices, endoscope technologies, and food processing and manufacturing. Andrew also has experience in patent validity, enforcement, and licensing, as well as ex parte reexaminations and inter partes reviews.
Prior to joining COJK, Andrew was with the University of Washington's technology transfer office, where his most recent role was as a senior patent portfolio manager responsible for managing all aspects of the patent portfolio for chemistry and life sciences inventions across the university.
Andrew earned his J.D. from Seattle University School of Law and received his B.S. and his M.S. degrees in chemistry from the University of Washington. Andrew is recognized in International Asset Management’s 2023 guide, IAM Patent 1000 – The World's Leading Patent Professionals.